Aeroflex Industria De Aerosol Ltda. - 728186 - 05/22/2026

Why It Matters

Non‑response jeopardizes Aeroflex’s access to the U.S. market, exposing the company to product detentions, loss of FDA registration, and broader supply‑chain disruptions for OTC drug distributors.

Key Takeaways

• FDA issued Warning Letter for non‑response to records request
• Facility listed as OTC drug manufacturer under FDA registration
• Failure may trigger product detentions at U.S. border
• Company must respond within 15 working days to avoid sanctions
• Potential delisting and inspection if compliance not demonstrated

Pulse Analysis

The FDA’s warning to Aeroflex underscores the agency’s aggressive stance on foreign manufacturers that neglect record‑keeping obligations. Under section 704(a) of the FD&C Act, firms must promptly provide manufacturing and quality‑assurance data when requested. Non‑compliance not only breaches legal requirements but also raises red flags about product integrity, prompting the FDA to consider detaining shipments under section 801(a)(3). For companies exporting over‑the‑counter drugs to the United States, maintaining an open line of communication with the agency is essential to avoid costly hold‑ups at customs and potential loss of market access.

For Aeroflex, the immediate priority is to submit a comprehensive response within the 15‑day window, clarifying its current manufacturing activities, updating drug listings, or formally deregistering if it has ceased production. The letter also offers the option to schedule an on‑site inspection, which could provide a path to reinstating confidence in its quality‑system controls. Failure to act swiftly may result in the FDA withholding approval for any new drug applications, effectively freezing the company’s pipeline for U.S. distribution and eroding relationships with importers and distributors.

The broader industry implication is a reminder that global supply chains are increasingly scrutinized. Companies operating outside the United States must align their documentation practices with FDA expectations, including timely electronic responses and transparent record‑keeping. Investing in robust compliance programs not only mitigates regulatory risk but also strengthens market credibility, a critical factor as consumers and regulators alike demand higher standards for safety and efficacy in OTC medications.